BLU 667

Drug Profile

BLU 667

Alternative Names: BLU667

Latest Information Update: 08 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Blueprint Medicines
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Proto oncogene protein c ret inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-small cell lung cancer; Solid tumours; Thyroid cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 04 Jun 2018 BLU 667 licensed to CStone Pharmaceuticals in China, Macau, Taiwan and Hong Kong
  • 15 Apr 2018 Efficacy, adverse events and pharmacokinetics data from the phase I ARROW trial in Solid Tumours released by Blueprint Medicines
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top